Lessons from VTE registries: the RIETE experience

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 25-33

  Monreal, Manuel ^a   Trujillo Santos, Javier ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

cancer; registry; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANEMIA; BLEEDING; CANCER MORTALITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC DISEASE; IMMOBILIZATION; INCIDENCE; LEUKOCYTE COUNT; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; NEOPLASM; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SOLID TUMOR; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SPAIN; VENOUS THROMBOEMBOLISM;

EID: 61649115169     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.12.003     Document Type: Review

References (38)

1. Monreal M., Falgá C., Valdés M., et al., RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 4 (2006) 1950-1956
2. Kearon C., Kahn S., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn.). Chest 133 (2008) 454S-545S
3. Levitan N., Dowlati A., Remick S., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 78 (1999) 285-291
4. Carson J.L., Kelley M.A., Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med 326 (1992) 1240-1245
5. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
6. Sorensen H., Mellemkjaer L., Olsen J., et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
7. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn.). Chest 133 (2008) 381S-453S
8. Trujillo-Santos J., Prandoni P., Rivron-Guillot K., et al., RIETE Investigators. Clinical outcome in patients with venous thromboembolism and hidden cancer. Findings from the RIETE Registry. J Thromb Haemost 6 (2008) 251-255
9. Gore J.M., Appelbaum J.S., Greene H.L., et al. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96 (1982) 556-560
10. Goldberg R.J., Seneff M., Gore J.M., et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 147 (1987) 251-253
11. Baron J.A., Gridley G., Weiderpass E., et al. Venous thromboembolism and cancer. Lancet 351 (1998) 1077-1080
12. Sorensen H.T., Mellemkjaer L., Steffensen F.H., et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
13. Prandoni P., Lensing A.W.A., Büller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
14. Piccioli A., and Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol 106 (2001) 13-17
15. Sorensen H.T., Mellemkjaer L., Olsen J.H., et al. Prognosis of cancer associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
16. Lee A.Y.Y. Screening for occult cancer in patients with idiopathic venous thromboembolism: no. J Thromb Haemost 1 (2003) 2273-2274
17. Monreal M., Fernandez-Llamazares J., Perandreu J., et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 78 (1997) 1316-1318
18. Piccioli A., and Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost 1 (2003) 2271-2272
19. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 162 (2002) 1729-1735
20. Lee A.Y.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 34 (2003) 146-153
21. Deitcher S.R., Kessler C.M., Merli G., et al., ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12 (2006) 389-396
22. Hull R.D., Pineo G.F., Brant R.F., et al., LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 120 (2007) 72-82
23. Trujillo-Santos J., Nieto J.A., Tiberio G., et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100 (2008) 435-439
24. Hutten B.A., Prins M.H., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 (2000) 3078-3083
25. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
26. Kearon C. Long-term management of patients after venous thrombo-embolism. Circulation 110 Suppl. I (2004) I-10-I-18
27. Kuijer P.M., Hutten B.A., Prins M.H., et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159 (1999) 457-460
28. Ruiz-Giménez N., Suárez C., González R., et al., RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100 (2008) 26-31
29. Trujillo-Santos J., diMicco P., Iannuzzo M.T., et al., RIETE Investigators. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100 (2008) 905-911
30. Kasuga I., Makino S., Kiyokawa H., et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92 (2001) 2399-2405
31. Maltoni M., Caraceni A., Brunelli C., et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations. A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23 (2005) 6240-6248
32. Shankar A., Wang J.J., Rochtchina E., et al. Association between circulating white blood cell count and cancer mortality. Arch Intern Med 166 (2006) 188-194
33. Gripp S., Moeeler S., Bölke E., et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25 (2007) 3313-3320
34. Weeks J.C., Cook E.F., O'Day S.J., et al. Relationship between cancer patient's predictions of prognosis and their treatment preferences. JAMA 279 (1998) 1709-1714
35. Christakis N.A., and Lamont E.B. Extent and determinants of error in doctor's prognoses in terminally ill patients: prospective cohort study. BMJ 320 (2000) 469-472
36. Lamont E.B., and Christakis N.A. Complexities in prognostication in advanced cancer. JAMA 290 (2003) 98-104
37. Vigano A., Dorgan M., and Buckingham J. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14 (2000) 363-374
38. Prandoni P., Trujillo-Santos J., Surico T., et al., RIETE Investigators. Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE Registry. Haematologica 93 (2008) 1432-1434